The Duke Cancer Institute (DCI) wants to assure our patients that the safety of our patients, their loved ones, our team members and the community at large remains our highest priority. We are closely monitoring this rapidly evolving situation and are implementing all necessary precautions to prevent the spread of infection.

For the latest information about how we are keeping our community safe, please visit www.dukehealth.org.

Faculty Members

Co-chaired by Daniel George, MD, and Brant Inman, MD, Associate Director of Urologic Research; the DCI Center for Prostate & Urologic Cancers team includes rising stars and world-renown physicians and researchers in genitourinary cancer.

Staffed by medical, urologic and radiation oncologists, our multi-disciplinary center offers the most comprehensive treatment options available. Our brilliant investigators move discoveries forward at an astounding speed, accelerating and expanding pioneering work in the prostate and urologic cancer field.

GU Leadership

Urologic Oncology

Samuel H. Eaton, MD

Thomas A. Longo, MD

Cary N. Robertson, MD

Michael N. Ferrandino, MD

Judd W. Moul, MD

Brant A. Inman, MD, MS
Lab: Inman

Thomas J. Polascik, MD
Lab: Polascik

Medical Oncology

Andrew Armstrong, MD, ScM
Lab: Armstrong

William R. Berry, MD

Michael R. Harrison, MD

Daniel J. George, MD
Lab: Patierno/George/Freedman

Sundhar Ramalingam, MD

Radiation Oncology

Carol A. Hahn, MD

Scott L. Sailer, MD

Bridget F. Koontz, MD

Jordan Torok, MD

W. Robert Lee, MD, MEd, MS

Radiology

David Enterline, MD

Chuck Spritzer, MD

Rajan Gupta, MD

Terence Wong, MD, PhD

Olga G. James, MD

Michael R. Zalutsky, PhD, MA

Pathology

Jiaoti Huang
Lab: Huang

Translational Science

Biostatistics & Bioinformatics

Patrick Healy, MS

Gary Lipton, MS, PhD

Susan Halabi, PhD

Kouros Owzar, PhD

Terry Hyslop, PhD

Hereditary Cancer Genetics

Survivorship

Aaron Lentz, MD

John Ragsdale, MD

Kevin Oeffinger, MD

Andrew Peterson, MD